Sotera Health (NASDAQ:SHC) Releases FY 2025 Earnings Guidance

Sotera Health (NASDAQ:SHC - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.700-0.760 for the period, compared to the consensus earnings per share estimate of 0.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Analysts Set New Price Targets

A number of equities analysts recently commented on SHC shares. Barclays decreased their target price on Sotera Health from $17.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday. The Goldman Sachs Group began coverage on shares of Sotera Health in a research report on Friday, December 6th. They set a "neutral" rating and a $14.00 price objective on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $17.00 target price on shares of Sotera Health in a report on Thursday, November 21st. Finally, Citigroup raised their price target on Sotera Health from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $15.92.

Sotera Health Stock Down 6.3 %

NASDAQ SHC traded down $0.79 on Monday, hitting $11.68. The stock had a trading volume of 2,333,034 shares, compared to its average volume of 1,012,844. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of 46.72 and a beta of 1.91. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.08. The business's fifty day moving average price is $13.45 and its 200 day moving average price is $14.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.